In a report released today, Graig Suvannavejh from Mizuho Securities maintained a Hold rating on Cerevel Therapeutics Holdings (CERE – Research Report), with a price target of $25.00. The company’s shares closed last Friday at $22.47.
According to TipRanks, Suvannavejh is an analyst with an average return of -5.7% and a 44.74% success rate. Suvannavejh covers the Healthcare sector, focusing on stocks such as Axsome Therapeutics, Bioxcel Therapeutics, and Terns Pharmaceuticals.
In addition to Mizuho Securities, Cerevel Therapeutics Holdings also received a Hold from Berenberg Bank’s Caroline Palomeque in a report issued on August 3. However, on August 4, Stifel Nicolaus maintained a Buy rating on Cerevel Therapeutics Holdings (NASDAQ: CERE).
See today’s best-performing stocks on TipRanks >>
CERE market cap is currently $3.54B and has a P/E ratio of -8.81.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of CERE in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
ARYA Sciences Acquisition Corp II is a blank check company.
Read More on CERE:
- Cerevel Therapeutics downgraded to Neutral from Buy at BofA
- Cerevel Therapeutics price target lowered to $41 from $45 at H.C. Wainwright
- Cerevel Therapeutics Reports Second Quarter 2023 Financial Results and Business Updates
- Cerevel Therapeutics reports Q2 EPS (63c), consensus (65c)
- Cerevel Therapeutics Holdings Inc (CERE) Q2 Earnings Cheat Sheet
